Financial Performance - Operating revenue for Q1 2023 was CNY 58,924,811.64, representing a year-on-year decline of 32.79%[11] - Net profit attributable to shareholders for Q1 2023 was CNY 5,623,307.50, down 63.17% from the same period last year[11] - The basic earnings per share for Q1 2023 was CNY 0.07, down 74.07% compared to the same period last year[12] - Gross profit for Q1 2023 was ¥10,723,546.57, down from ¥26,070,163.09 in Q1 2022, indicating a decrease of about 58.8%[45] - Net profit for Q1 2023 was ¥5,688,786.31, compared to ¥15,268,841.14 in Q1 2022, reflecting a decline of approximately 62.7%[46] - The total comprehensive income for Q1 2023 was ¥5,688,786.31, down from ¥15,268,841.14 in Q1 2022, reflecting a decrease of about 62.7%[47] Cash Flow and Assets - The company reported a net cash flow from operating activities of -CNY 19,892,433.69, a decrease of 166.96% compared to the previous year[11] - Cash and cash equivalents were reported at CNY 126,529,528.29, compared to CNY 192,703,332.20 in the previous period, representing a significant decline of approximately 34.3%[33] - Operating cash flow for Q1 2023 was negative at -¥19,892,433.69, contrasting with a positive cash flow of ¥29,708,153.56 in Q1 2022[48] - The total cash and cash equivalents at the end of the period stood at $126.19 million, down from $15.76 million previously[51] Revenue and Sales - The average selling price of quercetin decreased by 46.88% from CNY 823,600 per ton to CNY 437,500 per ton, contributing to the revenue decline[13] - The sales revenue of Diosmin increased by 19.53% year-on-year, while the sales revenue of Berberine increased by 97.34%[14] - The total revenue for the company reached 57,997,891, representing a 76.67% increase compared to the previous period[21] Assets and Liabilities - Total assets as of March 31, 2023, were CNY 430,779,352.64, a decrease of 2.20% compared to the end of 2022[11] - The company's total liabilities decreased to CNY 34,817,293.65 from CNY 50,225,567.49, marking a reduction of about 30.5%[35] - The total equity attributable to shareholders increased to CNY 395,962,058.99 from CNY 390,247,751.40, reflecting a growth of approximately 1.8%[35] - The company's current assets totaled CNY 356,806,508.56, down from CNY 378,983,354.45, indicating a decrease of about 5.83%[33] Commitments and Compliance - The company has confirmed that there are no ongoing litigation or arbitration matters during the reporting period[24] - The company has maintained compliance with all regulatory requirements during the reporting period[24] - The actual controller has committed to not engaging in competitive activities with the company, and this commitment is currently being fulfilled[25] - The company is committed to implementing measures to stabilize stock prices as approved by the shareholders' meeting within three years post-listing[26] Research and Development - Research and development expenses increased to CNY 3,482,350.98 in Q1 2023 from CNY 3,082,665.80 in Q1 2022, reflecting a growth of 13%[42] - The company plans to focus on market expansion and new product development in the upcoming quarters[40] - The company plans to enhance its quercetin production capacity through automation and continuous R&D efforts, which are expected to increase sales in the future[14]

证券代码：833230 证券简称：欧康医药 公告编号：2023-042 一、 说明会类型 成都欧康医药股份有限公司（以下简称"公司"）于 2023 年 4 月 13 日在北 京证券交易所指定信息披露平台（www.bse.cn）披露了《2022 年年度报告》（公 告编号：2023-016）及《2022 年年度报告摘要》（公告编号：2023-017），为方便 广大投资者更全面深入了解公司年度经营业绩的具体情况，加强与投资者的互 动交流，公司拟召开 2022 年年度报告业绩说明会。 二、 说明会召开的时间、地点 （一）会议召开时间：2023 年 4 月 28 日 15:00-16:00。 （二）会议召开地点 公司定于 2023 年 4 月 28 日（周五）15:00-16:00 在上海证券报官网举办 2022 年年度报告业绩说明会，本次年报业绩说明会将采用网络远程的方式举行，投资 者可登陆上海证券报官网中国证券网（https://roadshow.cnstock.com）参与本次年 报业绩说明会。 三、 参加人员 公司董事长、总经理：赵卓君先生 公司董事会秘书、财务负责人：叶丽蓉女士 公司保荐代表人：罗泽先生 成都 ...

Company Achievements and Recognition - In 2022, Chengdu Okay Pharmaceutical Co., Ltd. was awarded the title of "Little Giant" enterprise by the Ministry of Industry and Information Technology in July[5]. - The company successfully went public on the Beijing Stock Exchange on December 9, 2022[5]. - The National Medical Products Administration approved the listing application for the chemical raw material drug (Diosmin) on October 27, 2022[5]. - The company is recognized as a national high-tech enterprise and has been included in the list of national "specialized, refined, and innovative" small giant enterprises[49]. Financial Performance - The company's operating revenue for 2022 was RMB 269,435,957.14, a decrease of 10.44% compared to RMB 300,858,164.15 in 2021[30]. - The net profit attributable to shareholders for 2022 was RMB 33,662,612.94, down 19.69% from RMB 41,916,154.19 in 2021[30]. - The total assets at the end of 2022 reached RMB 440,473,318.89, an increase of 104.27% from RMB 215,629,712.12 in 2021[32]. - The total liabilities decreased by 30.14% to RMB 50,225,567.49 in 2022 from RMB 71,894,404.96 in 2021[32]. - The net assets attributable to shareholders increased by 171.50% to RMB 390,247,751.40 in 2022 from RMB 143,735,307.16 in 2021[32]. - The basic earnings per share for 2022 was 0.57, a decrease of 21.92% from 0.73 in 2021[30]. - The company's gross profit margin for 2022 was 22.51%, down from 24.30% in 2021[30]. - The company achieved total revenue of 269.44 million yuan, a decrease of 31.42 million yuan or 10.44% compared to the same period last year[52]. - Net profit was 33.66 million yuan, a decline of 8.10 million yuan or 19.40% year-on-year, primarily due to a 19.69% drop in revenue from the company's main product series[52]. Risks and Challenges - The company faces risks related to the expiration of product quality certifications, which could adversely affect its operations if not renewed[11]. - International trade environment changes could impact the company's overseas sales, particularly in developed markets like Europe, the US, and Japan[11]. - The company is exposed to risks from fluctuations in raw material supply and prices, which could significantly affect its financial performance[12]. - The company has identified potential risks related to the inability to timely digest new production capacity, which could impact economic benefits from investment projects[13]. - The company’s core product, Quercetin, may face market growth challenges if promotional efforts do not meet expectations[13]. - The company is heavily reliant on overseas markets for product sales, which poses risks if international policy or economic conditions change[118]. - The company is at risk of losing core technical personnel, which could impact production and operational efficiency[117]. Research and Development - The company has established a technical innovation system combining product R&D and technology application, focusing on the development of natural vitamin P compounds[46]. - The company has received multiple certifications including EuGMP, FSSC22000, HACCP, ISO22000, ISO9001, HALAL, and KOSHER, enhancing its market credibility[47]. - The company aims to become a global leader in the application of natural vitamin P compounds, with a focus on sustainable development and safety[45]. - The company has formed partnerships with institutions like the Chinese Academy of Sciences and universities for collaborative R&D[46]. - The company continues to focus on the development of new products and technologies, aiming to expand into domestic markets for raw pharmaceuticals, functional food ingredients, food additives, feed additives, and cosmetic raw materials[54]. - The company has a total of 27 patents, including 4 invention patents, showcasing its strong technical foundation in the plant extraction field[62]. - The company has initiated research on the production process of the EMIQ technology, which is currently in the small-scale testing phase, with the goal of developing new products and entering new markets[99]. Market and Industry Trends - In 2022, China's plant extract exports reached 3.53 billion USD, a year-on-year increase of 16.5%[57]. - The global market for plant extracts is expected to reach 59.4 billion USD by 2025, driven by increasing consumer demand for natural and healthy products[57]. - The competitive landscape of the plant extract industry in China is characterized by a low concentration of firms, with 88% of export companies earning less than 1 million USD[60]. - The company is positioned to benefit from supportive policies aimed at the health management and traditional medicine sectors, which will enhance the market for plant extracts[59]. Corporate Governance and Compliance - The company has established a new corporate governance system during the reporting period[190]. - The company has implemented key internal controls related to revenue recognition to mitigate risks associated with improper revenue reporting[102]. - The company has conducted thorough audits of its inventory measurement processes to ensure accuracy and compliance with accounting standards[104]. - The company has committed to strict compliance with profit distribution policies and measures to address any violations of these commitments[125]. - The company has established a mechanism to ensure equal rights and protection for all shareholders[192]. Future Plans and Investments - The company plans to expand its domestic market by developing raw materials for pharmaceuticals, functional food ingredients, and food additives[113]. - The company has established a subsidiary in the United States to develop new products and facilitate cross-border e-commerce sales[113]. - The company plans to publicly issue shares to unspecified qualified investors and list on the Beijing Stock Exchange[199]. - The company plans to use the raised funds for technical transformation projects, working capital supplementation, and repayment of bank loans[147]. - The technical transformation project in Chengdu is expected to enhance production capacity[147]. Employee and Management - The company has a total of 53,484,865 shares held by directors, supervisors, and senior management, representing 70.70% of the total shares[160]. - The total number of employees increased from 206 to 208, with a net addition of 2 employees during the reporting period[167][168]. - The employee compensation policy includes regular adjustments based on performance evaluations and annual assessments[169]. - The company emphasizes training and development for employees to enhance their skills and performance[169]. Environmental and Social Responsibility - The company emphasizes its commitment to social responsibility, including timely tax payments and environmental protection, while providing quality services to customers[107]. - The company has implemented a strict management system for hazardous waste and chemicals, ensuring compliance with relevant laws and regulations[188]. - The company has maintained a "zero accident" safety and environmental protection policy, with increased investment in safety and environmental measures[190].

Financial Performance - The company reported a revenue of ¥274,201,797.20 for 2022, a decrease of 8.86% compared to the previous year[3]. - Net profit attributable to shareholders was ¥34,720,762.18, down 17.17% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was ¥31,115,942.64, reflecting a decline of 22.15%[5]. - Basic earnings per share decreased to ¥0.46, a drop of 36.99% from the previous year[5]. Assets and Equity - Total assets at the end of the reporting period reached ¥442,298,206.94, an increase of 105.12% year-on-year[5]. - Shareholders' equity attributable to the company was ¥391,536,339.84, up 172.40% compared to the beginning of the year[5]. - The company issued 18,085,981 new shares in December 2022, which diluted earnings per share[7]. Impact Factors - The decline in performance was primarily due to the impact of COVID-19 and power restrictions in Chengdu during the summer[6]. Strategic Focus - The company is focusing on technological innovation and expanding new products and markets to enhance its core competitiveness[6]. Financial Reporting - The financial data presented is preliminary and has not been audited, with final figures to be disclosed in the annual report[8].